Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonafexor in Alport Syndrome
NCT06425055Phase 2Completed
- Sponsor
- ENYO Pharma
- Start
- Aug 2024
- Primary completion
- Sep 2025
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of vonafexor in Alport syndrome, sponsored by ENYO Pharma. Primary endpoint: Treatment-Emergent Adverse Event at 26 weeks. Started Aug 2024; status: completed.
02
Drugs
vonafexor
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on NCT06425055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425055.